VEGFA and neoplasm: HIF-1A activates survival pathways in tumor cells and increases production of angiogenic growth factors such as VEGF or fibroblast growth factor (FGF) and others, thereby inducing more aggressive tumor growth, influencing endothelial cell behavior, and promoting therapy resistance [7, 8].